Study of asthma treatment with the administration of Pyrostegia venusta extract in a mouse model of allergic asthma

• Grant number: 14/07616-0
• Support Opportunities: Scholarships in Brazil - Master
• Start date: August 01, 2014
• End date: August 16, 2015
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Agreement: Coordination of Improvement of Higher Education Personnel (CAPES)
• Principal Investigator: Marcos de Carvalho Borges
• Grantee: Andiamira Cagnoni Balestra
• Host Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
• Associated research grant: 10/20600-4 - Study of asthma prevention and treatment with the administration of viable and heat-killed Saccharomyces cerevisiae in a murine model of allergic asthma, AP.JP

Abstract

Introduction: Asthma, a prevalent chronic inflammatory disease characterized byairway hyperresponsiveness, inflammation, and remodeling, is responsible for important morbimortality worldwide. The available drugs for asthma treatment can elicit different responses and numerous side effects. Therefore, new drugs for asthma treatment are highly desirable. Pyrostegia venusta, a native plant of the Brazilian cerrado, has been shown to have anti-inflammatory and antioxidative properties. There is no study of Pyrostegia venusta in the treatment of asthma. Objective: To evaluate the effect of Pyrostegia venusta on asthma treatment in an animal modeland the mechanisms involved. Methods: Male Balb/c mice will be used in study. The mice will be sensitized twice with Ovalbumin (OVA) Intraperitoneally (ip), one week apart, and, after one week, will be challenged with OVA intranasally for three days consecutively. Mice will be treated with extract of Pyrostegia venusta (100 mg/kg), ip, for three days consecutively, during OVA challenges. Control mice will receive normal saline on the same days. Twenty-four hours after the last challenge, mice will be ventilated with a small-animal ventilator (FlexiVent®), and in vivo hyperresponsiveness will be evaluated with increasing concentrations of methacholine aerosol. After ventilation, Bronchoalveolar Lavage (BAL) will be collected, and total and differential cells will be quantified. Furthermore, the inflammation will be evaluated by performing ELISA for IL-4, IL-5, IL-10, IL-13, IFN-g e TGF-b. Histochemistry will be performed in the lungs to quantify inflammation, collagen and mucus. Real time PCR will be realized in lung tissue to measure inflammatory cytokine, such as IL-4, IL-5, IL-10, IL-13, IFN-g e TGF-b. Significance: The demonstration of anti-inflammatory effect of Pyrostegia venusta extract in an animal model of asthma can lead to the development of new drugs for asthma treatment. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

BALESTRA, ANDIAMIRA CAGNONI; SANDY, CAMILA MIRA; RAMALHO, FERNANDO; JORDAO JUNIOR, ALCEU AFONSO; TALEB CONTINI, SILVIA HELENA; CREVELIN, EDUARDO JOSE; CARMONA, FABIO; PEREIRA, ANA MARIA S.; BORGES, MARCOS C.. Aqueous Pyrostegia venusta (Ker Gawl.) Miers extract attenuates allergen-induced asthma in a mouse model via an antioxidant mechanism. JOURNAL OF ASTHMA, v. 58, n. 6, FEB 2020. (10/20600-4, 14/07616-0)

Academic Publications

(References retrieved automatically from State of São Paulo Research Institutions)

BALESTRA, Andiamira Cagnoni. Study of the administration of two plant extracts P. venusta in the treatment of asthma in an animal model. 2016. Master's Dissertation - Universidade de São Paulo (USP). Faculdade de Medicina de Ribeirão Preto (PCARP/BC) Ribeirão Preto.